glp-1 news 2025 november Poll: 1 in 8 Adults Say They Are Currently Taking a Drug for Weight Loss, Diabetes or Another Condition, Even as Half Say the Drugs Are Difficult to Afford The GLP-1 Access Gap: Mapping

Retatrutide is an investigational triple agonist (GLP-1, GIP, and glucagon receptors) not yet licensed by the MHRA or EMA, with Phase 2 data suggesting significant weight reduction but Phase 3 confirmation still required

Some may remain on therapy

Look for evidence-based programs with progressive overload built in

However, it is also currently widely discussed as a slimming injection

The MucT strain in Lemme Metabolism has been evaluated in clinical research and shown to support markers of metabolic health and weight maintenance. In addition to Akkermansia muciniphila, the capsules combine Black Ginger Root Extract, known to support visceral fat reduction and healthy energy metabolism, as well as Chromium, a natural mineral that could play a role in carbohydrate, lipid and protein metabolism by potentiating insulin action